Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
NCT06853925 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2026-01-16
Summary
The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are:
1. Can patients easily use and benefit from the RAI Support intervention?
2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care?
This research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment.
Researchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being.
Participants will:
1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks.
2. Use the assigned website once a week for up to four weeks.
3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms.
4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.
Conditions
- Thyroid Neoplasms
Interventions
- BEHAVIORAL
-
Radioactive Iodine Support (RAI Support)
RAI Support consists of multimedia content (images, videos, text, audio, and infographics across different website pages) that is written at an 8th grade reading level. RAI Support uses patient materials that are visually diverse to appeal to patients from different racial and ethnic backgrounds and inclusion of all genders. RAI Support users can access short (\~3 minutes or less) clinician-approved symptom management education videos and follow clinician-led video-guided activities such as nutrition management for dry mouth. In addition, RAI Support contains infographic pages about specific symptoms of RAI (e.g., salivary, lacrimal, and nasal symptoms with strategies for symptom management) and a resources page consisting of a printable treatment summary and survivorship plan to bring to provider appointments and access to evidence-based stress-management resources such as relaxation recordings.
- OTHER
-
Treatment as Usual (TAU)
The American Cancer Society (ACS) website on Radioactive Iodine (Radioiodine)Therapy for Thyroid Cancer is the TAU comparison. This website is a reputable and trusted source of information about cancer, with relevant content and web availability. Using the ACS website allows participants in both groups to receive information (addressing ethical concerns) through a website (similar delivery mode for information).
Sponsors & Collaborators
-
Georgetown University
lead OTHER
Principal Investigators
-
Alaina Carr, PhD · Georgetown University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-02
- Primary Completion
- 2027-02-28
- Completion
- 2027-02-28
Countries
- United States
Study Locations
More Related Trials
-
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818 ·Status: COMPLETED ·Phase: PHASE3
-
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT04290663 ·Status: RECRUITING ·Phase: PHASE3
-
Personalized Treatment in Thyroid Disorders
NCT03517579 ·Status: RECRUITING ·Phase: NA
-
Hyperthyroid Follow-Up Study
NCT02989103 ·Status: COMPLETED
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT05668962 ·Status: RECRUITING ·Phase: PHASE2
-
Low-dose Radioiodine Ablation in Graves' Disease
NCT03110835 ·Status: COMPLETED
-
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
NCT02278198 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00001730 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
NCT04868045 ·Status: WITHDRAWN ·Phase: PHASE1
-
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
NCT06558981 ·Status: RECRUITING ·Phase: PHASE3
-
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
NCT00970359 ·Status: COMPLETED ·Phase: NA
-
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
NCT01837745 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism
NCT03574051 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
NCT00295763 ·Status: COMPLETED ·Phase: PHASE3
-
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
NCT06073223 ·Status: COMPLETED ·Phase: NA
-
AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid
NCT04463719 ·Status: COMPLETED ·Phase: NA
-
99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients
NCT03065218 ·Status: TERMINATED ·Phase: PHASE4
-
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
NCT04892303 ·Status: RECRUITING ·Phase: PHASE1
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
NCT06961084 ·Status: RECRUITING ·Phase: PHASE2
-
Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer
NCT03300284 ·Status: COMPLETED
-
Block-replacement Therapy During Radioiodine Therapy
NCT00150124 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
NCT00196729 ·Status: COMPLETED ·Phase: PHASE3
-
Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing
NCT06629272 ·Status: RECRUITING ·Phase: NA
-
Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer
NCT01744769 ·Status: UNKNOWN
-
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
NCT04354324 ·Status: RECRUITING ·Phase: NA